Environmental or self-antigens and homotypic interactions bring about BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other alerts from the microenvironment and rising the activation of anti-apoptotic and proliferation pathways.Duvelisib was the second PI3K inhibitor approved from the FDA, also according to a pha